Hydrocortisone
Hydrocortisone Sodium Succinate — Short-Acting Glucocorticoid with Clinically Relevant Mineralocorticoid Activity
🧬 Mechanism of Action & Target Pathway
Glucocorticoid & Mineralocorticoid Receptor Activation
- Lipophilic molecule diffuses across plasma membrane and binds cytoplasmic glucocorticoid receptors (GR) and mineralocorticoid receptors (MR).
- Receptor-ligand complex homodimerizes and translocates into the nucleus.
- Transrepression: Inhibits NF-κB and AP-1 transcription factors, suppressing pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and inducible nitric oxide synthase (iNOS).
- Transactivation: Upregulates anti-inflammatory proteins (lipocortin-1/annexin A1, IκB-α, IL-10) and increases adrenergic receptor density/sensitivity on vascular smooth muscle.
- MR Activation: Promotes renal distal tubular Na⁺/water reabsorption and K⁺ excretion, supporting intravascular volume in adrenal crisis.
Pharmacokinetics & Pharmacodynamics (PK/PD) — Hydrocortisone
receptor occupancy⚖️ ICU Clinical Reasoning
Why I Choose It (Indications & Strengths)
- ✓Supported by the 2024 SCCM focused update for adult septic shock (conditional recommendation) and severe bacterial community-acquired pneumonia (strong recommendation for corticosteroids). CAPE COD used IV hydrocortisone 200 mg/day with protocolized duration/taper and reduced 28-day mortality in its enrolled severe-CAP population.
- ✓Hydrocortisone is the standard corticosteroid used in vasopressor-dependent septic shock when an ongoing/escalating vasopressor requirement persists after appropriate initial resuscitation; do not require one universal norepinephrine dose-duration threshold.
- ✓Hydrocortisone is standard emergency glucocorticoid therapy for acute adrenal crisis; high stress-dose hydrocortisone provides sufficient mineralocorticoid activity during the acute phase, with fludrocortisone introduced later when appropriate for primary adrenal insufficiency as hydrocortisone is reduced.
- ✓Shorter biological half-life (8–12h) facilitates quick dose titration and rapid recovery of HPA axis compared to long-acting dexamethasone.
- ✓For septic shock, 200 mg/day hydrocortisone is commonly used either intermittently (for example 50 mg every 6 hours) or by continuous infusion; current 2026 sepsis guidance does not establish continuous infusion as universally superior.
Why I Don't (Limitations & Gaps)
- ✕Current sepsis guidance supports IV corticosteroids for adults with septic shock; it does not support routine corticosteroids for sepsis without shock solely because infection is present.
- ✕Mineralocorticoid action induces fluid retention and hypernatremia, which can worsen pulmonary edema in volume-overloaded ARDS.
- ✕Hyperglycemia is more frequent with corticosteroids and may require adjustment of the ICU glucose-control regimen; avoid unsupported universal incidence figures.
- ✕Longer or higher cumulative corticosteroid exposure can increase adverse effects including hyperglycemia, infection risk and neuromuscular complications; tapering depends on indication, duration and prior steroid exposure rather than one universal day cutoff.
💉 Dosing & Administration Protocols
Septic shock: commonly hydrocortisone 200 mg/day IV, either as 50 mg every 6 hours or continuous infusion; current 2026 SSC does not designate continuous infusion as preferred. Acute adrenal crisis: 100 mg hydrocortisone IV/IM immediately, then 200 mg/24 h (continuous infusion preferred by endocrine emergency guidance, or 50 mg every 6 h) until clinical recovery and specialist-guided reduction.
Syndrome-Specific Regimens
200 mg/day IV continuous infusion initiated early (within 24h of ICU admission). 8-day course with adaptive 8-to-14 day taper per protocol.
Note: Reduced 28-day mortality (6.2% vs 11.9%, p=0.006) in severe CAP requiring ICU admission (PSI class V, mechanically ventilated, or PaO2/FiO2 < 300).
Hydrocortisone 200 mg/day IV is a common regimen, given as intermittent doses or continuous infusion. Duration and discontinuation/taper strategy should follow the patient's course and local protocol rather than a mandatory 5–7 day course.
Note: Consider when septic shock remains dependent on ongoing/escalating vasopressor support after appropriate initial resuscitation; exact timing is individualized rather than tied to one mandatory norepinephrine cutoff.
100 mg IV/IM immediately, then 200 mg/24h continuous IV infusion (or 50 mg IV/IM q6h) until clinical recovery; reduce and transition to maintenance replacement with endocrine guidance according to the underlying adrenal disorder.
Note: At doses ≥100 mg/day, hydrocortisone provides maximal mineralocorticoid receptor saturation; fludrocortisone is unnecessary during acute high-dose IV phase.
Do not use a fixed 7-day hydrocortisone course solely because the label CIRCI is applied. In septic shock, steroid use should follow current sepsis guidance; in suspected primary/secondary adrenal insufficiency, follow endocrine emergency guidance.
Note: Do not require ACTH stimulation testing before giving indicated corticosteroids in septic shock or suspected adrenal crisis; diagnostic testing must not delay emergency adrenal-crisis treatment.
Renal Function Dosing
| CrCl Range | Dose Adjustment |
|---|---|
| Any CrCl / AKI / ESRD | No fixed renal-replacement-specific dose is established for the ICU indications listed here; use the indication-specific regimen and monitor sodium, potassium, glucose, fluid status and clinical response. |
Dialytic Clearance (HD / CRRT)
🩺 Organ Failure Considerations
Mineralocorticoid activity can cause sodium retention, edema, and hypokalemia. In severe oligoanuric AKI, observe for fluid accumulation.
Hepatic clearance is impaired in cirrhosis or acute liver failure, leading to prolonged circulating half-life and enhanced glucocorticoid exposure; monitor glucose closely.
⚠️ Toxicity & Safety Warnings
Major Warnings
- 🚨Marked hyperglycemia: increases risk of secondary bacterial and fungal infections; blood glucose protocol required.
- 🚨ICU-Acquired Weakness / Critical Illness Myopathy: synergistic myopathy risk when combined with neuromuscular blocking agents (NMBAs).
- 🚨Steroid-induced leukocytosis: demargination of polymorphonuclear neutrophils can cause WBC elevation without signifying new infection.
- 🚨HPA-axis suppression risk rises with greater dose/duration and prior glucocorticoid exposure; withdrawal strategy should reflect cumulative exposure rather than a rigid 7–14 day cutoff.
🔄 Bedside Drug Interactions
| Interacting Drug | Mechanism | Clinical Consequence | Mandatory ICU Action |
|---|---|---|---|
| Neuromuscular Blockers (e.g., Cisatracurium, Rocuronium) | Synergistic inhibition of muscle protein synthesis and receptor down-regulation | Prolonged critical illness myopathy and delayed ventilator weaning | Minimize duration of concurrent NMBAs and steroids; monitor train-of-four and perform daily wake-up trials. |
| CYP3A4 Inducers (e.g., Rifampin, Phenytoin, Carbamazepine) | Accelerated hepatic 11β-HSD and CYP3A4 metabolism of hydrocortisone | Subtherapeutic corticosteroid levels and treatment failure in adrenal crisis | Strong enzyme inducers can increase glucocorticoid clearance; in adrenal insufficiency or inadequate clinical response, involve endocrinology/pharmacy rather than applying an unsupported universal 50–100% increase. |
| Insulin / Oral Antidiabetics | Opposing physiological effect on hepatic gluconeogenesis and peripheral insulin sensitivity | Severe hyperglycemia | Monitor glucose and treat clinically significant hyperglycemia according to the ICU glucose-management protocol; IV insulin is not automatically required solely because hydrocortisone is started. |
📊 Monitoring & TDM Protocols
Required Monitoring Parameters
- ▪ Blood glucose at a frequency appropriate to illness severity, nutrition and insulin therapy; use the local ICU glycemic-control target/protocol
- ▪ Serum potassium, sodium, and chloride daily (or q12h in unstable shock)
- ▪ Vasopressor requirement and shock trajectory; discontinuation/taper strategy depends on duration, indication and local protocol
- ▪ Surveillance for secondary superinfections (fungemia, VAP, bacteremia)
- ▪ Mental status/delirium as clinically appropriate
Evidence Status
CurrentLast Medically Reviewed
2026-08-29
Evidence Checked Through
2026-08-29
📚 Evidence Traceability & Guideline Citations
"Current U.S. prescribing information was reviewed for dosing, organ-failure handling, pharmacology, warnings and interactions relevant to this ICU monograph."
"Acute adrenal crisis: give hydrocortisone 100 mg IV/IM immediately, then 200 mg/24 h (continuous infusion or 50 mg every 6 h) until clinical recovery and specialist guidance."
"SCCM 2024 conditionally supports corticosteroids in adult septic shock and strongly recommends corticosteroids for severe bacterial CAP; it recommends against high-dose/short-duration regimens >400 mg/day hydrocortisone equivalent for <3 days in septic shock."
"CAPE COD randomized controlled trial demonstrated early IV hydrocortisone 200 mg/day continuous infusion significantly reduced 28-day mortality in severe CAP admitted to the ICU."
"Surviving Sepsis Campaign 2026 conditionally suggests IV corticosteroids for adults with septic shock; 200 mg/day hydrocortisone is the dominant regimen in practice and major trials, but the guideline does not require a single vasopressor-dose threshold or continuous-infusion strategy."
"ADRENAL trial showed hydrocortisone 200 mg/day continuous infusion significantly accelerated shock reversal and reduced ICU stay, without 90-day mortality difference."
"APROCCHSS trial showed hydrocortisone plus fludrocortisone significantly reduced 90-day all-cause mortality in refractory septic shock."
🩺 Bedside Patient Scenarios
Vasopressor-Refractory Septic Shock
Scenario: A 64-year-old patient with septic shock remains vasopressor-dependent despite appropriate initial resuscitation and source-control management.
Rationale: Current guidelines conditionally support IV corticosteroids in adult septic shock. Hydrocortisone increases the probability of shock reversal but should not be described as treating a proven CIRCI diagnosis or guaranteeing survival benefit in an individual patient.
Acute Adrenal Crisis in Known Addisonian
Scenario: A 32-year-old with primary adrenal insufficiency presents with severe gastroenteritis, vomiting, MAP 50 mmHg, Na⁺ 124 mEq/L, K⁺ 6.1 mEq/L, and blood glucose 52 mg/dL.
Rationale: Hydrocortisone provides both life-saving glucocorticoid receptor activation and mineralocorticoid activity (at doses >100 mg/day), correcting hypotension and electrolyte disturbances without needing fludrocortisone acutely.
🎯 Exam Traps & Board Misconceptions
Do not give steroids merely because infection/sepsis is present, but also do not carry the older ≥0.25 mcg/kg/min-for-4-hours threshold forward as a mandatory 2026 rule. Use the current septic-shock recommendation and patient-specific risk/benefit.
Avoid presenting an exact mineralocorticoid equivalence as a bedside conversion rule. Endocrine emergency guidance supports 100 mg hydrocortisone immediately followed by 200 mg/24 h, with fludrocortisone added later when appropriate for primary adrenal insufficiency as glucocorticoid dosing falls.
Continue Learning
Shock: Foundational Critical Care Framework
Cellular dysoxia, DO2/VO2 physiology, the 4 shock phenotypes, dynamic fluid responsiveness (PLR/PPV) vs fluid tolerance (VExUS), and vasoactive pharmacology.
Septic Shock
The subset of sepsis with profound circulatory and cellular/metabolic abnormality — clinically identified by a vasopressor requirement to maintain MAP ≥ 65 mmHg plus lactate > 2 mmol/L despite adequate fluid resuscitation.
Septic Shock Resuscitation
2026 SSC-aligned fluids, early norepinephrine, dynamic reassessment, and perfusion endpoints
Atrial Fibrillation with Hemodynamic Instability
Emergency cardioversion, recurrent AF during critical illness, and post-acute follow-up
Acute Hypotension & Undifferentiated Shock
Rapid bedside hemodynamic categorization: confirming MAP < 65 mmHg, assessing peripheral perfusion, POCUS cardiac/IVC profiling, and differentiating hypovolemic, distributive, cardiogenic, and obstructive etiologies.
Refractory Shock Despite High-Dose Vasopressors
Advanced multimodal hemodynamic rescue: second-line vasopressors (vasopressin, angiotensin II), inotropic augmentation, stress-dose steroids, metabolic correction, and mechanical circulatory support evaluation.